Tarceva news from FiercePharma
NewsSPOTLIGHT: NICE rejects Roche drug as too costly
Roche's lung cancer med Tarceva got the goodbye gong from the U.K.'s National Institute for Clinical Excellence, which ruled that the drug wasn't a cost-effective option for treating non-small cell Read more...
Roche, Cipla trade jabs on Tarceva
We turn to India for updates on another cancer-drug battle, this one between Roche's brand-name Tarceva and Cipla's copycat version, Erlocip. A Roche distributor tattled to India's Drug Controller Read more...
Court sends Mircera case to ITC
Another chapter in what's becoming a long Mircera saga: A federal appeals court ruled that Roche could import the anemia drug so long as it wasn't for sale--but sent the case back to the Read more...
Thai official backs off licensing fight
The brief ray of patent-respecting sunlight from Thailand has gone behind the old Read more...
ALSO NOTED: Wyeth wins FDA blessing for hemophilia med; India considers compulsory licensing;
> Wyeth got the FDA's nod for its hemophilia drug Xyntha, which also got the green light to prevent surgical bleeding in patients with the disease; the company was named in a related patent Read more...
ALSO NOTED: Japan to get Roche's Tarceva next week; Barr sues two generics makers over Seasonale;
> Roche's Japanese unit Chugai Pharmaceutical is preparing to launch the lung-cancer drug Tarceva, approved in Japan in October for treatment of the non-small cell form of the disease. Read more...
ALSO NOTED: Tarceva gets Japan's nod; FDA blesses Novartis arthritis remedy;
> Japanese drug regulators approved Roche's lung cancer drug Tarceva, made by OSI Pharmaceuticals. Read more...
Roche cuts UK price on cancer drug
Here's a strategy for penetrating the market when state healthcare won't yet pay for your drug: Cut the price. Roche is doing just that with Tarceva, its lung cancer treatment, until the UK's Read more...
| Press ReleasesPRESS RELEASE: Tarceva approved for lung cancer in Japan Tarceva approved for lung cancer in Japan Roche, Chugai and OSI Pharmaceuticals, Inc. announced today that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with Read more... |
Get more Tarceva coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight